Overview

A Study of Endostar Combined With Chemotherapy and Immunotherapy in Lung Squamous Cell Carcinom

Status:
Recruiting
Trial end date:
2025-05-30
Target enrollment:
Participant gender:
Summary
To explore the efficacy and safety of immune checkpoint inhibitor combined with endostar and chemotherapy in the treatment of advanced lung squamous cell carcinoma (stage IIIB-IV).
Phase:
Phase 4
Details
Lead Sponsor:
Xuzhou Medical University
Treatments:
Endostar protein
Immune Checkpoint Inhibitors